Evaluation of New Magnetic Resonance (MR) Imaging and Spectroscopy Software

Evaluation of New Magnetic Resonance (MR) Imaging and Spectroscopy Software Multiparametric MRI for Response Assessment of Tumors The proposed work will include 2 primary aims and 1 secondary aim (to be completed if time permits). The number of patients scanned is based on the study enrollment at BMDACC. 1) We will apply compressed sensing-based strategy for acceleration of Magnetic Resonance Spectroscopic Imaging (CS-MRSI) and assess the quality of data. Where feasible, we will explore selective spectral excitation strategy in combination with CS-MRSI. The gold standard of comparison will be standard spectroscopic imaging, using in vitro phantoms and the HCC/met liver lesion and prostate adenocarcinoma model. We will evaluate the accuracy and quality of the peaks obtained by CS-MRSI as compared to standard spectroscopy technique. In addition, the metabolic changes of liver lesions will be monitored over time by CS-MRSI as compared to standard technique. We also hope to correlate citrate and choline changes with biopsy results for adenocarcinoma. 2) Our second aim is to implement multiparametric MR technique for tumor response assessment. This will include combining the CS-MRSI, diffusion, and DCE sequences. The disease model will again involve liver HCC/met and prostate adenocarcinoma. 3) If time permits, we will apply the compressed sensing technique to other sequences, such as LAVA/DISCO sequences. With compressed sensing, it is expected to make these fast gradient echo sequences even faster to minimize motion and susceptibility artifacts. Other potential sequences for acceleration includes angiographic sequences which currently uses keyhole technique. Adding undersampling would allow even better temporal resolution without sacrificing spatial resolution.